Project portfolio

IRLAB’s project portfolio is based on the company’s research platform ISP and contains a growing number of candidates in development.

Discovery
Pre clinical
Phase I
Phase IIA
Phase IIB
Phase III
Parkinson’s disease –
levodopa-induced dyskinesias (LIDs)
Mesdopetam *(IRL790) D3 antagonist
Phase III ready
Parkinson’s disease –
Psychosis
Mesdopetam *(IRL790) D3 antagonist
Phase II ready
Parkinson’s disease – Falls
Pirepemat (IRL752) PFC enhancer
Phase IIB
Parkinson’s disease – Dementia
Pirepemat (IRL752) PFC enhancer
Phase IIA
Neurology – Apathy

In collaboration with The Michael J. Fox Foundation and MSRD/Otsuka
IRL757
Phase I
Neurology – Cognitive function
IRL942
Preclinical
Parkinson’s disease
IRL1117
Preclinical